Bruker Announces Resignation of Chief Financial Officer and Appointment of Interim Chief Financial Officer
21 May 2015 - 6:03AM
Business Wire
Bruker Corporation (NASDAQ: BRKR) today announced that on May
19, 2015, Mr. Charles F. Wagner, Jr., Executive Vice President and
the Chief Financial Officer (CFO) of Bruker since July 2012,
submitted his resignation, effective June 12, 2015, in order to
pursue other interests. Mr. Wagner has informed the Company that he
has accepted a position as Chief Financial Officer of
Ortho-Clinical Diagnostics, Inc., and will commence service in that
position in late June 2015. Mr. Wagner’s resignation is not the
result of any dispute or disagreement with the Company or any
matter relating to the Company’s accounting practices or financial
statements.
Frank Laukien, Bruker’s President & CEO, commented, “I would
like to thank Charlie Wagner for doing an outstanding job as our
Chief Financial Officer over the last 3 years, and for his previous
contributions to Bruker as a director. Charlie has been a key
architect of our Innovation & Transformation strategy, and has
helped Bruker strengthen its leadership, processes and systems.
While our transformation is substantially planned and well
underway, more work remains to be done, as Bruker is committed to
becoming a great company. I am grateful for Charlie’s positive
impact on Bruker, and wish him continued success in his new
role.”
Mr. Wagner said, “I am very proud of my five year affiliation
with Bruker, including two years on the Board of Directors and
three years as CFO. During that time, we have worked very hard to
build upon Bruker’s outstanding legacy and transform the company
for the better. Bruker is a stronger company today, because of
those efforts.”
Mr. Wagner is expected to continue in his role as Bruker’s Chief
Financial Officer until his departure from the Company, and he will
work during the next few weeks to ensure an orderly transition of
his responsibilities. Bruker intends to initiate a search and until
such time as a new CFO is appointed, Mr. Anthony L. Mattacchione,
an executive officer and the Company’s Senior Vice President of
Finance & Accounting, will serve as interim CFO, effective upon
Mr. Wagner’s departure. Mr. Mattacchione joined the Company in
February 2013, and is currently responsible for the Company's
global finance and accounting functions, including corporate
accounting, financial planning & analysis, treasury, tax,
shared financial services, internal controls and internal audit.
Prior to joining the Company, Mr. Mattacchione served as Chief
Financial Officer of EMD Millipore Corporation, a subsidiary of
Merck KGaA, and as Vice President, Controller and Chief Accounting
Officer of Millipore Corporation.
About Bruker Corporation
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance scientific
research instruments and high-value analytical solutions enable
scientists to explore life and materials at molecular, cellular and
microscopic levels. In close cooperation with our customers, Bruker
is enabling innovation, productivity and customer success in life
science molecular research, in applied and pharma applications, and
in microscopy, nano-analysis and industrial applications, as well
as in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit: http://www.bruker.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150520006393/en/
Bruker CorporationJoshua Young, 978-663-3660
x1479joshua.young@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024